Cardinal Health Inc's Suppliers recorded an increase in sales by 2.92 % year on year in Q3 2026, from the previous quarter, sales fell by -7.62 %, Cardinal Health Inc recorded an increase in cost of sales by 10.78 % year on year, relative to one quarter ago cost of sales fell by -7.57 % in Q3.
Cardinal Health Inc's Suppliers recorded an increase in sales by 2.92 % year on year in Q3 2026, from the previous quarter, sales fell by -7.62 %, Cardinal Health Inc recorded increase in cost of sales by 10.78 % year on year, compare to one quarter ago cost of sales fell by -7.57 % in Q3.
Cardinal Health sources raw materials at market prices or prices linked to commodity indices, with some finished goods partially priced based on commodity price indices. Commodity prices fluctuated during fiscal 2026, influenced in part by the conflict in Iran. The company conducts sensitivity analysis on its forecasted direct commodity exposure, which decreased by approximately $34 million from June 30, 2025, to June 30, 2026, resulting in a forecasted exposure of $457 million for the upcoming fiscal year. As of June 30, 2026, there were no outstanding commodity contracts in the hedging program. Cardinal Health maintains prime vendor relationships to streamline purchasing and reduce costs for customers. The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals and over-the-counter healthcare products to healthcare providers and retailers, provides services to pharmaceutical manufacturers including distribution and inventory management, and offers consulting and patient support services for specialty pharmaceutical products. This segment also provides pharmacy management services and repackages generic pharmaceuticals and over-the-counter products.
Cardinal Health Inc's Comment on Supply Chain
Cardinal Health sources raw materials at market prices or prices linked to commodity indices, with some finished goods partially priced based on commodity price indices. Commodity prices fluctuated during fiscal 2026, influenced in part by the conflict in Iran. The company conducts sensitivity analysis on its forecasted direct commodity exposure, which decreased by approximately $34 million from June 30, 2025, to June 30, 2026, resulting in a forecasted exposure of $457 million for the upcoming fiscal year. As of June 30, 2026, there were no outstanding commodity contracts in the hedging program. Cardinal Health maintains prime vendor relationships to streamline purchasing and reduce costs for customers. The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals and over-the-counter healthcare products to healthcare providers and retailers, provides services to pharmaceutical manufacturers including distribution and inventory management, and offers consulting and patient support services for specialty pharmaceutical products. This segment also provides pharmacy management services and repackages generic pharmaceuticals and over-the-counter products.
CAH's Suppliers Net Income grew by
CAH's Suppliers Net margin grew in Q3 to
5.43 %
18.81 %
CAH's Suppliers Net Income grew by 5.43 %
CAH's Suppliers Net margin grew in Q3 to 18.81 %
Cardinal Health Inc's Suppliers Sales Growth
in Q3 2026 by Industry
Sources:
Cardinal Health Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cardinal Health Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
22.21 %